Sepsis and Septic Shock: Current Treatment Strategies and New Approaches.
暂无分享,去创建一个
Zekai Halici | Elif Cadirci | Gizem Polat | Rustem Anil Ugan | Z. Halıcı | E. Çadırcı | R. A. Ugan | Gizem Polat
[1] E. Akpinar,et al. Comparative Study on Effects of Nebulized and Oral Salbutamol on a Cecal Ligation and Puncture-Induced Sepsis Model in Rats , 2014, Drug Research.
[2] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.
[3] Jonathan Cohen. The immunopathogenesis of sepsis , 2002, Nature.
[4] K. Reinhart,et al. Pathophysiology of Sepsis and Multiple Organ Dysfunction , 2011 .
[5] F. Atalay,et al. Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study , 2011, Clinical and experimental immunology.
[6] O. Deveci,et al. Antifungal Susceptibility and Risk Factors in Patients with Candidemia. , 2016, The Eurasian journal of medicine.
[7] Gavin D Perkins,et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. , 2016, The New England journal of medicine.
[8] David T. Huang,et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. , 2006, Annals of emergency medicine.
[9] B. Z. Altunkaynak,et al. &agr;-LIPOIC ACID AS A POTENTIAL TARGET FOR THE TREATMENT OF LUNG INJURY CAUSED BY CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS MODEL IN RATS , 2009, Shock.
[10] Y. Bayir,et al. The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.
[11] L. Carbonell,et al. Oxidative stress in critically ill patients with systemic inflammatory response syndrome , 2002, Critical care medicine.
[12] R. Hotchkiss,et al. The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.
[13] R. Bordet,et al. Pretreatment with peroxysome proliferator-activated receptor α agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock , 2005, Intensive Care Medicine.
[14] R. Balogun,et al. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. , 2005, Critical care medicine.
[15] A. Zangrillo,et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. , 2015, Journal of critical care.
[16] R. Bone,et al. Gram-negative sepsis. Background, clinical features, and intervention. , 1991, Chest.
[17] S. Atamanalp,et al. Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. , 2013, International immunopharmacology.
[18] E. Akpinar,et al. What is the role of renin inhibition during rat septic conditions: preventive effect of aliskiren on sepsis-induced lung injury , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.
[19] Z. Halıcı,et al. Evaluation of 5-HT7 Receptor Trafficking on In Vivo and In Vitro Model of Lipopolysaccharide (LPS)-Induced Inflammatory Cell Injury in Rats and LPS-Treated A549 Cells , 2017, Biochemical Genetics.
[20] P. Gøtzsche,et al. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] S. Sriskandan,et al. The pathogenesis of septic shock. , 1995, The Journal of infection.
[22] Mitchell M. Levy,et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.
[23] S. Ünal,et al. Factors influencing prognosis in bacteremia due to gram-negative organisms: evaluation of 448 episodes in a Turkish university hospital. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] K. Tracey,et al. HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.
[25] Roger C. Bone. Definitions for Sepsis and Organ Failure , 1993 .
[26] W. Wiersinga,et al. Inflammation, endothelium, and coagulation in sepsis , 2008, Journal of leukocyte biology.
[27] K. Polderman,et al. Drug intervention trials in sepsis: divergent results , 2004, The Lancet.
[28] D. Remick,et al. The pathogenesis of sepsis. , 2011, Annual review of pathology.
[29] J. Bakker,et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.
[30] A. Oral,et al. The Effects of Montelukast on Antioxidant Enzymes and Proinflammatory Cytokines on the Heart, Liver, Lungs, and Kidneys in a Rat Model of Cecal Ligation and Puncture–Induced Sepsis , 2011, TheScientificWorldJournal.
[31] D. Pittet,et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] H. Bruining,et al. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. , 1998, Critical care medicine.
[33] D. Cook,et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.
[34] S. Bhagwanjee,et al. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. , 1997, Critical care medicine.
[35] S. Pillai,et al. Innate immunity. , 1996, Current opinion in immunology.
[36] C. Hinds,et al. Anabolic strategies in critical illness. , 2002, Current opinion in pharmacology.
[37] E. Camporesi,et al. Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-α production and lung neutrophil sequestration , 2001, European Journal of Applied Physiology.
[38] I. İnce,et al. Effects of Propofol and Midazolam on the Inflammation of Lungs after Intravenous Endotoxin Administration in Rats. , 2015, The Eurasian journal of medicine.
[39] Miet Schetz,et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.
[40] L. McIntyre,et al. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity , 2005, Canadian Medical Association Journal.
[41] R. Bone,et al. Sepsis: a new hypothesis for pathogenesis of the disease process. , 1997, Chest.
[42] James A Russell,et al. Management of sepsis. , 2006, The New England journal of medicine.
[43] M. Berger,et al. Improving nutritional support in critically Ill septic patients: glutamine alone or in combination? , 2002, Nutrition.
[44] Peter A. Ward,et al. Harmful molecular mechanisms in sepsis , 2008, Nature Reviews Immunology.